Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 257.19 million. The enterprise value is 294.85 million.
| Market Cap | 257.19M |
| Enterprise Value | 294.85M |
Important Dates
The last earnings date was Thursday, September 17, 2026.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | Jul 20, 2026 |
Share Statistics
Lavipharm has 170.78 million shares outstanding. The number of shares has increased by 1.29% in one year.
| Current Share Class | 170.78M |
| Shares Outstanding | 170.78M |
| Shares Change (YoY) | +1.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.53% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 46.29.
| PE Ratio | 46.29 |
| Forward PE | n/a |
| PS Ratio | 3.69 |
| PB Ratio | 4.61 |
| P/TBV Ratio | 49.82 |
| P/FCF Ratio | 44.11 |
| P/OCF Ratio | 36.42 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.01, with an EV/FCF ratio of 50.51.
| EV / Earnings | 51.76 |
| EV / Sales | 4.23 |
| EV / EBITDA | 21.01 |
| EV / EBIT | 33.02 |
| EV / FCF | 50.51 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.22 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 2.92 |
| Debt / FCF | 7.01 |
| Interest Coverage | 5.08 |
Financial Efficiency
Return on equity (ROE) is 10.22% and return on invested capital (ROIC) is 7.49%.
| Return on Equity (ROE) | 10.22% |
| Return on Assets (ROA) | 4.23% |
| Return on Invested Capital (ROIC) | 7.49% |
| Return on Capital Employed (ROCE) | 9.36% |
| Weighted Average Cost of Capital (WACC) | 8.92% |
| Revenue Per Employee | 229,788 |
| Profits Per Employee | 18,768 |
| Employee Count | 306 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, Lavipharm has paid 2.05 million in taxes.
| Income Tax | 2.05M |
| Effective Tax Rate | 26.30% |
Stock Price Statistics
The stock price has increased by +87.65% in the last 52 weeks. The beta is 1.01, so Lavipharm's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +87.65% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 37.16 |
| Average Volume (20 Days) | 110,120 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 70.32 million and earned 5.74 million in profits. Earnings per share was 0.03.
| Revenue | 70.32M |
| Gross Profit | 33.15M |
| Operating Income | 9.00M |
| Pretax Income | 7.80M |
| Net Income | 5.74M |
| EBITDA | 13.39M |
| EBIT | 9.00M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 3.62 million in cash and 41.28 million in debt, with a net cash position of -37.66 million or -0.22 per share.
| Cash & Cash Equivalents | 3.62M |
| Total Debt | 41.28M |
| Net Cash | -37.66M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 56.36M |
| Book Value Per Share | 0.33 |
| Working Capital | 9.71M |
Cash Flow
In the last 12 months, operating cash flow was 7.13 million and capital expenditures -1.24 million, giving a free cash flow of 5.89 million.
| Operating Cash Flow | 7.13M |
| Capital Expenditures | -1.24M |
| Depreciation & Amortization | 4.39M |
| Net Borrowing | 8.70M |
| Free Cash Flow | 5.89M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 47.14%, with operating and profit margins of 12.80% and 8.17%.
| Gross Margin | 47.14% |
| Operating Margin | 12.80% |
| Pretax Margin | 11.09% |
| Profit Margin | 8.17% |
| EBITDA Margin | 19.04% |
| EBIT Margin | 12.80% |
| FCF Margin | 8.37% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.33%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.33% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 58.87% |
| FCF Payout Ratio | 58.04% |
| Buyback Yield | -1.29% |
| Shareholder Yield | 0.04% |
| Earnings Yield | 2.21% |
| FCF Yield | 2.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
Lavipharm has an Altman Z-Score of 1.94 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.94 |
| Piotroski F-Score | 6 |